Advertisement

Topics

Lundbeck LLC Company Profile

07:43 EDT 20th June 2018 | BioPortfolio

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain disorders, including our work on therapies for people with challenging seizure disorders.


News Articles [66 Associated News Articles listed on BioPortfolio]

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will p...

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful.  Danish pharma Lundbeck has decided to ...

H. Lundbeck A/S: Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

-- Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones -- Foliglurax is a first-in-class t...

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office

Valby, Denmark, 2018-03-20 14:01 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 20 March 2018 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Dir...

Lundbeck takes risk on Parkinson’s treatment, €905m on table

CNS’ treatments are notoriously risky, especially those that are still at an early stage; however, Lundbeck has decided to take a calculated risk on Prexton Therapeutics and its sole candidate for P...

Lundbeck bulks up neuro pipeline with Prexton buy

As part of the deal, Lundbeck will add a first-in-class small-molecule compound, foliglurax, to its growing CNS repertoire.

Lundbeck targets 2020 for development of partnered schizophrenia candidate

Lundbeck has acquired an exclusive license to a research program aimed at a novel approach to treating…

Lundbeck to Acquire Prexton Therapeutics

Danish drugmaker Lundbeck has announced plans to buy Swiss drug developer Prexton Therapeutics in a deal worth up to €905 million. The deal would give Lundbeck global rights to Prexton’s fo...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Neoprofen [Lundbeck Inc.]

These highlights do not include all the information needed to use NeoProfen safely and effectively. See full prescribing information for NeoProfen. NeoProfen (ibuprofen lysine) Injection for intraveno...

Panhematin [Lundbeck Inc.]

Panhematin Hemin For Injection Rx only For intravenous infusion only.

Atryn [Lundbeck Inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Peganone [Lundbeck Inc.]

PEGANONE 250 mg Tablets (ethotoin tablets, USP) R Only

Cogentin [Lundbeck Inc.]

Cogentin® (benztropine mesylate injection) Rx only

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in ...

Companies [16 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...

Lundbeck

Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...

Psychotropics

The Lundbeck Institute is pleased to present Psychotropics Online, a comprehensive guide to CNS compounds and products.We have published Psychotropics since the 1960s in a printed handbook version, an...

Lundbeck Limited

As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmac...

More Information about "Lundbeck LLC" on BioPortfolio

We have published hundreds of Lundbeck LLC news stories on BioPortfolio along with dozens of Lundbeck LLC Clinical Trials and PubMed Articles about Lundbeck LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lundbeck LLC Companies in our database. You can also find out about relevant Lundbeck LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Corporate Database Quicklinks



Searches Linking to this Company Record